We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Pravastatin Found to Reduce Diabetes Onset

By HospiMedica staff writers
Posted on 30 Jan 2001
A study has discovered that pravastatin can reduce the risk of type 2 diabetes. More...
Conducted by researchers at the University of Glasgow (Scotland), the study was published in the January 23 issue of Circulation. Pravastatin is a drug used to lower cholesterol.

The researchers found that subjects on a placebo during the five years of the study had about a 3% chance of getting type 2 diabetes, while the risk of diabetes for those taking pravastatin was reduced by 30%. This finding follows further analysis of the West of Scotland Coronary Prevention Study. This study of 6,595 men with elevated cholesterol levels and no history of heart disease showed that pravastatinn reduced the risk of a first heart attack.

Although the 30% reduction for diabetes among pravastatin users was encouraging, the researchers say that further large randomized studies are needed to confirm the finding. One question that needs to be researched is whether all drugs of the statin family have this effect or whether the reduction is related to particular characteristics of pravastatin. Scientists will also seek to explain the underlying mechanisms that brought about this effect.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.